HER2Bi-BATs

EGFR2 bispecific antibody armed activated T cells (HER2Bi-BATs) is an adoptive cell therapy consisting of autologous T cells that are activated and expanded ex vivo and subsequently "armed" with a bispecific antibody. This bispecific antibody (BsAb) is typically a chemical heteroconjugate of an anti-CD3 monoclonal antibody (such as muromonab-CD3) and an anti-HER2/EGFR2 monoclonal antibody (such as trastuzumab). The therapy works by using the BsAb to bridge the activated T cells directly to HER2-expressing tumor cells, bypassing the requirement for major histocompatibility complex (MHC) recognition. This redirecting of T-cell cytotoxicity leads to the secretion of Th1 cytokines (IFN-gamma, TNF-alpha) and direct lysis of the target cancer cells. Developed primarily by Lawrence Lum and his team, this approach is being investigated for the treatment of HER2-positive malignancies, including breast and ovarian cancers, particularly in patients who have failed standard-of-care HER2-targeted therapies.

Other names

HER2 bispecific antibody armed activated T cellsHER-2 bispecific antibody armed activated T cellsHER 2 bispecific antibody armed activated T cellsanti-CD3 x anti-HER2 bispecific antibody armed activated T cellsanti-CD-3 x anti-HER2 bispecific antibody armed activated T cellsanti-CD 3 x anti-HER2 bispecific antibody armed activated T cellsEGFR2 bispecific antibody armed activated T cellsEGFR-2 bispecific antibody armed activated T cellsEGFR 2 bispecific antibody armed activated T cellsArmed activated T cells targeting HER2